Literature DB >> 30684079

Recommendations on the Diagnosis and Initial Management of Acute Variceal Bleeding and Hepatorenal Syndrome in Patients with Cirrhosis.

Frederik Nevens1, Paulo Lisboa Bittencourt2, Minneke J Coenraad3, Huiguo Ding4, Ming-Chih Hou5, Pierre-François Laterre6, Manuel Mendizabal7, Nayeli Xochiquetzal Ortiz-Olvera8, Julio D Vorobioff9, Wenhong Zhang10, Paolo Angeli11.   

Abstract

Cirrhosis is a serious and life-threatening condition which imposes a significant socioeconomic burden on affected individuals and healthcare systems. Cirrhosis can result in portal hypertension, which may lead to major complications, including acute variceal bleeding and hepatorenal syndrome. Without prompt treatment, these complications may be life-threatening. Over the past 2 decades, new treatment modalities and treatment strategies have been introduced, which have improved patients' prognosis, but the initial management of these severe complications continues to present a challenge. The present recommendations aim to increase clinicians' knowledge on the importance of early diagnosis and treatment, and to provide evidence-based management strategies to potentially, further improve patient outcomes. Special attention was given to the role of terlipressin. A comprehensive non-systematic literature search was undertaken to evaluate the evidence for the diagnosis and initial management of acute variceal bleeding and hepatorenal syndrome in patients with cirrhosis. Recommendations on the diagnosis and initial management of acute variceal bleeding and hepatorenal syndrome in patients with cirrhosis have been developed based on the best available evidence and the expert opinion of the consensus panel following a comprehensive review of the available clinical data. Prompt identification and timely treatment of acute variceal bleeding and hepatorenal syndrome are essential to reduce the burden.

Entities:  

Keywords:  Acute kidney injury; Acute variceal bleeding; Cirrhosis; Hepatorenal syndrome; Terlipressin; Vasoactive drugs

Mesh:

Year:  2019        PMID: 30684079     DOI: 10.1007/s10620-018-5448-y

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  88 in total

1.  Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2.

Authors:  Carlo Alessandria; Wilma Debernardi Venon; Alfredo Marzano; Claudio Barletti; Maurizio Fadda; Mario Rizzetto
Journal:  Eur J Gastroenterol Hepatol       Date:  2002-12       Impact factor: 2.566

Review 2.  Hepatorenal syndrome: pathophysiology and management.

Authors:  Hani M Wadei; Martin L Mai; Nasimul Ahsan; Thomas A Gonwa
Journal:  Clin J Am Soc Nephrol       Date:  2006-07-12       Impact factor: 8.237

3.  Terlipressin (triglycyl-lysine vasopressin) controls acute bleeding oesophageal varices. A double-blind, randomized, placebo-controlled trial.

Authors:  C Söderlund; I Magnusson; S Törngren; L Lundell
Journal:  Scand J Gastroenterol       Date:  1990-06       Impact factor: 2.423

4.  Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis.

Authors:  Ezequiel Rodríguez; Chiara Elia; Elsa Solà; Rogelio Barreto; Isabel Graupera; Alida Andrealli; Gustavo Pereira; Maria Poca; Jordi Sánchez; Mónica Guevara; Germán Soriano; Carlo Alessandria; Javier Fernández; Vicente Arroyo; Pere Ginès
Journal:  J Hepatol       Date:  2014-01-18       Impact factor: 25.083

Review 5.  The changing role of beta-blocker therapy in patients with cirrhosis.

Authors:  Phillip S Ge; Bruce A Runyon
Journal:  J Hepatol       Date:  2013-09-26       Impact factor: 25.083

6.  Early administration of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: the European Acute Bleeding Oesophageal Variceal Episodes (ABOVE) randomised trial.

Authors:  A Avgerinos; F Nevens; S Raptis; J Fevery
Journal:  Lancet       Date:  1997-11-22       Impact factor: 79.321

7.  Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.

Authors:  Marta Martín-Llahí; Marie-Noëlle Pépin; Mónica Guevara; Fernando Díaz; Aldo Torre; Alberto Monescillo; Germán Soriano; Carlos Terra; Emilio Fábrega; Vicente Arroyo; Juan Rodés; Pere Ginès
Journal:  Gastroenterology       Date:  2008-02-14       Impact factor: 22.682

Review 8.  Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club.

Authors:  V Arroyo; P Ginès; A L Gerbes; F J Dudley; P Gentilini; G Laffi; T B Reynolds; H Ring-Larsen; J Schölmerich
Journal:  Hepatology       Date:  1996-01       Impact factor: 17.425

9.  Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome.

Authors:  Sergio Neri; Davide Pulvirenti; Mariano Malaguarnera; Bruno M Cosimo; Gaetano Bertino; Luca Ignaccolo; Sebasiano Siringo; Pietro Castellino
Journal:  Dig Dis Sci       Date:  2007-10-16       Impact factor: 3.199

10.  U.K. guidelines on the management of variceal haemorrhage in cirrhotic patients.

Authors:  Dhiraj Tripathi; Adrian J Stanley; Peter C Hayes; David Patch; Charles Millson; Homoyon Mehrzad; Andrew Austin; James W Ferguson; Simon P Olliff; Mark Hudson; John M Christie
Journal:  Gut       Date:  2015-04-17       Impact factor: 23.059

View more
  2 in total

1.  The impact of albumin infusion on the risk of rebleeding and in-hospital mortality in cirrhotic patients admitted for acute gastrointestinal bleeding: a retrospective study of a single institute.

Authors:  Zhu Wang; Ya-Wen Xie; Qing Lu; Hai-Lin Yan; Xin-Bin Liu; Yi Long; Xian Zhang; Jin-Lin Yang
Journal:  BMC Gastroenterol       Date:  2020-06-23       Impact factor: 3.067

2.  Management of Decompensated Cirrhosis in the Surgical ICU: an American Association for the Surgery of Trauma Critical Care Committee Clinical Consensus Document.

Authors:  Anupamaa Seshadri; Rachel Appelbaum; Samuel P Carmichael; Joseph Cuschieri; Jason Hoth; Krista L Kaups; Lisa Kodadek; Matthew E Kutcher; Abhijit Pathak; Joseph Rappold; Sean R Rudnick; Christopher P Michetti
Journal:  Trauma Surg Acute Care Open       Date:  2022-08-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.